CC
LGND icon

Chicago Capital’s Ligand Pharmaceuticals LGND Stock Holding History

Chicago Capital’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$112M Buy
561,675
+252
+0% +$49.9K 3.02% 9
2025
Q4 		$106M Sell
561,423
-7,188
-1% -$1.38M 2.62% 9
2025
Q3 		$101M Sell
568,611
-3,214
-0.6% -$478K 2.48% 11
2025
Q2 		$65M Buy
571,825
+17,308
+3% +$1.85M 1.6% 23
2025
Q1 		$58.3M Buy
554,517
+2,929
+0.5% +$331K 1.65% 27
2024
Q4 		$59.1M Buy
551,588
+5,767
+1% +$652K 1.57% 27
2024
Q3 		$54.6M Buy
545,821
+30,875
+6% +$3.11M 1.52% 29
2024
Q2 		$43.4M Buy
514,946
+285,350
+124% +$22.7M 1.29% 32
2024
Q1 		$16.8M Sell
229,596
-1,915
-0.8% -$141K 0.51% 45
2023
Q4 		$16.5M Sell
231,511
-128,834
-36% -$7.6M 0.6% 41
2023
Q3 		$21.6M Sell
360,345
-63,674
-15% -$4.19M 1.01% 35
2023
Q2 		$30.6M Sell
424,019
-25,489
-6% -$1.91M 1.38% 33
2023
Q1 		$33.1M Buy
449,508
+130,454
+41% +$9.27M 1.65% 30
2022
Q4 		$21.3M Sell
319,054
-417,228
-57% -$27.1M 1.18% 32
2022
Q3 		$39.6M Buy
736,282
+17,556
+2% +$1.03M 2.29% 15
2022
Q2 		$40M Sell
718,726
-69,496
-9% -$3.94M 2.21% 16
2022
Q1 		$55.3M Buy
788,222
+88,583
+13% +$6.43M 2.38% 11
2021
Q4 		$67.4M Sell
699,639
-6,135
-0.9% -$567K 2.51% 14
2021
Q3 		$61.3M Sell
705,774
-29,931
-4% -$2.31M 2.33% 15
2021
Q2 		$60.2M Buy
735,705
+16,540
+2% +$1.38M 2.35% 16
2021
Q1 		$68.4M Buy
719,165
+185,600
+35% +$17.5M 2.89% 6
2020
Q4 		$33.1M Sell
533,565
-245,240
-31% -$14M 1.48% 30
2020
Q3 		$46.3M Buy
778,805
+347,981
+81% +$23.7M 2.38% 18
2020
Q2 		$30.1M Buy
+430,824
New +$27.3M 1.74% 25

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Chicago Capital's LGND Position: Q1 2026 in Review

Chicago Capital increased its Ligand Pharmaceuticals (LGND) stake by 0.04% in Q1 2026, buying an estimated $49.9K and bringing the position to 561,675 shares worth $112M. The position accounts for 3.02% of the portfolio, ranked #9.

Chicago Capital first reported a position in LGND in Q2 2020 and has held it in 24 quarters since. 357 funds tracked by Wall St. Rank hold LGND as of Q1 2026.

  • Chicago Capital held 561,675 shares of Ligand Pharmaceuticals worth $112M as of Q1 2026.
  • Chicago Capital bought 252 Ligand Pharmaceuticals shares in Q1 2026, an estimated $49.9K.
  • Ligand Pharmaceuticals made up 3.02% of Chicago Capital's portfolio in Q1 2026, its #9 holding.
  • Chicago Capital first reported a position in Ligand Pharmaceuticals in Q2 2020 and has held it in 24 quarters since.
  • 357 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2026.

Based on Chicago Capital's 13F filing for Q1 2026, filed 24 Apr 2026.